Apmonia_Therapeutics_reims
30 juillet 2020

Apmonia Therapeutics, a new biotech company in Reims, is seeking an Office Manager

-- ARTICLE UNIQUEMENT DISPONIBLE EN ANGLAIS --

Apmonia Therapeutics, the new biotech company achieved corporate organization and received i-Lab innovation award.

The company is developing its unique platform to generate peptidebased candidates selectively targeting the tumor microenvironment for the treatment of various cancer indications.

Incorporated in April 2019 in Reims (France) as a spin-off of CNRS (National Center for Scientific Research) UMR7369 MEDyC and Reims University,
Apmonia Therapeutics develops a new class of therapeutic peptides using a breakthrough technology that is the legacy of thirteen years of academic research.

The company recently achieved corporate organization, including Supervisory Board gathering biopharma industry well-renowned specialists, and a Clinical Advisory Board that brings together key opinion leaders with expertise in immune-oncology and targeted cancer indications.

About Apmonia Therapeutics

Created in April 2019, Apmonia Therapeutics is a biotechnology company based in Reims (France) dedicated to the development of anti-cancer therapies. Building on renowned expertise in oncology as well as in developing personalized medicine approaches, innovative technological approach and proprietary portfolio consist in selectively targeting the tumor microenvironment. Apmonia Therapeutics’ commitment is to offer therapeutic solutions for solid tumors that are refractory to available treatments (high rate of relapse and/or lack of targeted therapies), including orphan tumor pathologies with high unmet medical needs.

Apmonia Therapeutics is seeking an Office Manager to support management locally. This is a part-time position reporting to the CEO. It is an exciting opportunity to play a key role supporting Apmonia Therapeutics growth.

// Dowload the Office manager details PDF here (fiche de poste en anglais)

Contact
Apmonia Therapeutics: Albin JEANNE, CEO
contact@apmonia-therapeutics.com

S'inscrire à la newsletter